Video

Dr. Locke on the Results of the ZUMA-7 Trial in Relapsed/Refractory Large B-Cell Lymphoma

Frederick Locke, MD, discusses the results of the phase 3 ZUMA-7 trial in patients with large B-cell lymphoma that were presented at the 2021 ASH Annual Meeting & Exposition.

Frederick Locke, MD, vice chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy Program, co-leader, Immuno-Oncology, Moffitt Cancer Center, discusses the results of the phase 3 ZUMA-7 trial (NCT03391466) in patients with large B-cell lymphoma ​(LBCL) that were presented at the 2021 ASH Annual Meeting & Exposition.

The primary end point of the ZUMA-7 trial was event-free survival (EFS), defined as time from randomization to the earliest date of disease progression including death due to any cause or commencement of different anti-lymphoma therapy, Locke says. The data showed that over 90% of patients randomized received CAR T-cell therapy with axicabtagene ciloleucel (axi-cel; Yescarta), whereas about 30% of patients received a definitive autologous hematopoietic stem cell transplant, Locke explained.

The findings from the study demonstrated a median EFS of 8.3 months with axi-cel vs 2 months with standard of care in patients with relapsed/refractory LBCL, Locke continues. Notably, the 24-month EFS rate was 40.5% compared with 16.3%, respectively. This means that at 2 years after randomization, over 40% of patients who received axi-cel arm did not require additional therapy and remained in remission, Locke concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center